Author: Andrei Bilog M.Sc., CAPM

Cancer immunotherapy continues to reshape oncology, moving beyond traditional chemotherapy and radiation toward strategies that harness the patient’s immune system to recognize and destroy malignant cells. Among the most promising developments in this field is PhotonPharma’s personalized cancer vaccine platform, Innocell™, which is entering human clinical trials after years of preclinical innovation and technology refinement.

PhotonPharma, a biotechnology company based in Fort Collins, Colorado, has developed a novel autologous therapeutic vaccine designed to stimulate a patient’s own immune system against their tumor. The Innocell approach uses a patient’s tumor cells that are rendered incapable of replication but retain their metabolic activity and antigenic properties. By exposing tumor tissue to riboflavin (vitamin B2) and ultraviolet (UV) light using proprietary photochemical methods, PhotonPharma produces inactivated cells that present a broad array of antigens to the immune system without the risk of causing new tumors. This platform thereby aims to train the immune system to recognize and attack residual cancer cells throughout the body.

In early 2024, PhotonPharma received clearance from the U.S. Food and Drug Administration (FDA) to initiate a first-in-human Phase I clinical study of its Innocell vaccine in patients with advanced (Stage III/IV) ovarian cancer. This trial will primarily assess safety, tolerability, and early immune response indicators in participants receiving the autologous vaccine produced from their own tumor tissue. Manufacturing for the clinical study is being conducted in partnership with the City of Hope Comprehensive Cancer Center’s Los Angeles campus.

This milestone marks a significant inflection point for the company, transitioning a once experimental immunotherapy from preclinical models toward human testing — a critical step in determining clinical viability and therapeutic potential.

The scientific foundation of PhotonPharma’s technology lies in research demonstrating that inactivating tumor cells with riboflavin and UV light preserves key tumor antigens while preventing replication, enabling strong immunogenicity. A peer-reviewed preclinical study published in Vox Sanguinis showed that tumor cells treated with this method induced dendritic cell maturation, increased interferon-γ (IFN-γ) production, and generated tumor-specific antibody responses. When formulated with appropriate adjuvants and administered as a vaccine in murine cancer models, the approach led to reduced tumor growth, decreased metastatic disease, and prolonged survival compared with controls.

Additional peer-reviewed work has evaluated the safety and tolerability of Innocell in client-owned dogs with spontaneous cancers, demonstrating biological activity consistent with an induced immune response and suggesting a favorable acute safety profile.

PhotonPharma’s innovation has attracted attention within both scientific and commercial circles. In September 2025, the company was awarded U.S. Patent No. 12,280,039 B2 for its method of producing photochemically inactivated cancer cells with preserved immunogenicity — a key component of its vaccine strategy. This patent strengthens PhotonPharma’s intellectual property and underscores the broad potential application of its platform across multiple solid tumor types.

Moreover, PhotonPharma leadership continues to engage with the broader immunotherapy community. CEO and Chief Scientific Officer Dr. Raymond Goodrich has been invited to present at major industry conferences, including the 2nd Annual Personalized Cancer Vaccine Summit, where the company’s scalable manufacturing and immune activation strategies have been showcased alongside efforts from leading biopharmaceutical organizations.

While PhotonPharma’s approach represents an innovative fusion of personalized medicine and immunotherapy, several challenges remain. The Phase I clinical study will provide initial data on safety and immune activation, but larger trials will be necessary to determine whether this strategy can achieve meaningful clinical benefit — such as improved survival or durable responses — in human patients. Additionally, the logistical complexity of producing autologous vaccines tailored to each individual patient continues to present manufacturing and cost hurdles that must be addressed as the technology advances. Nonetheless, the preservation of native tumor antigens and the potential for broad immune engagement position Innocell as a compelling candidate in the cancer vaccine landscape.